相关实验视频

Updated: Jul 15, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

针对原发性骨髓纤维化病的治疗方法的最新进展

William Vainchenker^1,2,3, Nasrine Yahmi^1,2,3, Violaine Havelange^4,5

¹INSERM, UMR1287, Gustave Roussy, Villejuif, France.

Faculty reviews

|September 29, 2023

概括

像骨髓纤维化 (MF) 这样的骨髓扩散性瘤 (MPN) 的新疗法旨在改变症状管理之外的疾病进展. 有希望的策略包括端粒酶抑制和针对突变克隆的向疗法.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

经典的BCR-ABL1阴性髓扩散性瘤 (MPNs),包括原发性髓纤维化 (PMF),真多细胞血症 (PV) 和基本血栓细胞血症 (ET),是由JAK2信号驱动的.
PMF和二次MF是侵略性的MPN,除了干细胞移植之外,其治疗选择有限.
目前的JAK抑制剂提供症状缓解,但不会显著改变疾病的进展.

研究的目的:

审查目前针对MPN的治疗策略,重点关注髓纤维化.
探索针对超越JAK抑制的疾病机制的新型治疗方法.
确定未来的治疗方向,以修改MPN进展并改善患者的治疗结果.

主要方法:

对MPN遗传学,病理生理学和治疗剂的当前文献的综述.
对针对表观遗传调节,亡,细胞周期,细胞因子和信号通路的新兴治疗方法的分析.
评估包括干扰素α,端粒酶抑制和免疫治疗在内的新策略.

主要成果:

雅克抑制剂可以改善MF的症状和脏大小,但缺乏改变疾病的效果.
新的药物向特定的分子通路,旨在纠正细胞衰竭和抑制纤维化.
有前途的方法包括端粒酶抑制,组合疗法 (JAK抑制剂与BCL2/BCL-xL或BET抑制剂),以及针对JAK2V617F,MPL和calreticulin突变的向疗法.

结论:

在开发用于MF的修改疾病的治疗方法方面,正在取得重大进展.
未来的疗法可能涉及针对性抑制特定突变和途径,可能与JAK抑制剂结合.
更好地了解MPN生物学正在为更有效,更少毒性治疗铺平道路.

关键词:

骨髓增殖性瘤是一种多发性瘤骨髓纤维化骨髓纤维化治疗方法的治疗方法.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Introduction to Fibroblasts

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...